HopeStage
Back to all studies
CompletedNCT04285515

Lumateperone for Depression Linked to Bipolarity and Major Depression

About this title

Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder

Read the official source — NCT04285515

Researchers compared Lumateperone and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.

Medication studyAges 18–75Multiple countries
The study in practice

Understand this study

What did researchers investigate?

Researchers compared Lumateperone and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.

Who was this study for?

Listed age limits: 18 years to 75 years.

Listed locations
Garden Grove and 41 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: February 27, 2020
Recruitment status
Completed
Enrollment listed in the registry
488
Sponsor
Intra-Cellular Therapies, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States, Bulgaria, Russia, ...
Age range
From 18 Years to 75 Years
Official registry ID
NCT04285515
Official title
Show the full official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Lumateperone Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression) or Major Depressive Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Garden Grove, United States · Oceanside, United States · Sherman Oaks, United States

32 more locations
  • Lauderhill, United States
  • Miami, United States
  • Orange City, United States
  • Atlanta, United States
  • Decatur, United States
  • O'Fallon, United States
  • Cedarhurst, United States
  • New York, United States
  • Charlotte, United States
  • Bellevue, United States
  • Burgas, Bulgaria
  • Kardzhali, Bulgaria
  • Plovdiv, Bulgaria
  • Rousse, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Veliko Tarnovo, Bulgaria
  • Vratsa, Bulgaria
  • Moscow, Russia
  • Saint Petersburg, Russia
  • Tomsk, Russia
  • Yekaterinburg, Russia
  • Belgrade, Serbia
  • Kovin, Serbia
  • Kragujevac, Serbia
  • Kyiv, Ukraine
  • Lviv, Ukraine
  • Odesa, Ukraine
  • Poltava, Ukraine
  • Smila, Ukraine
  • Vinnytsia, Ukraine
  • Russia

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared Lumateperone and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.

Who is behind this study?

The study sponsor is Intra-Cellular Therapies, Inc.

Did this study involve medication?

Yes. The study involved medication, including Lumateperone and Placebos.

Who was this study for?

Listed age limits: 18 years to 75 years.

Want to explore more studies?

Explore studies